Blog
What Happens After the Intervention Stops: Weight Regain in Trial Extensions
A trial that stops at the end of the treatment period only tells half the story. Some of the most informative data in weight research come from what happens next. Two designs, extension follow-up and randomized withdrawal, have produced consistent findings that matter for interpreting every weight-loss result.
Key takeaways
- In the STEP 1 extension, participants regained about two thirds of the lost weight within a year of stopping semaglutide.
- In SURMOUNT-4, people switched from tirzepatide to placebo regained weight, while those who continued kept losing.
- Cardiometabolic markers also moved back toward baseline.
- These are published trial results, not guidance.
Extension follow-up
The STEP 1 trial, reported in 2021, randomized adults with overweight or obesity to semaglutide or placebo alongside lifestyle intervention for 68 weeks. An extension, published in 2022 by Wilding and colleagues, followed participants one year after treatment stopped. On average, those who had been on semaglutide had lost roughly 17 percent of body weight by week 68, and had regained about two thirds of that loss by one year later. Improvements in blood pressure, glucose and lipids also moved back toward their starting values.
Randomized withdrawal
The SURMOUNT-4 trial, published in 2023, first gave all participants tirzepatide for 36 weeks, then randomly assigned them to continue or switch to placebo for the next 52 weeks. Those who switched to placebo regained about 14 percent of their body weight on average, while those who continued lost a further 5 to 6 percent. A randomized withdrawal design is powerful because it isolates the effect of stopping.
Why this fits the physiology
The results are what you would predict from the defenses described in why weight loss plateaus: when an intervention that suppresses appetite is removed, lower leptin, higher hunger signals and a reduced energy expenditure remain (see the appetite hormone map). The body’s drive to return to its former weight reasserts itself.
Why it matters for reading research
- Look for follow-up. A result measured only while an intervention is running describes the effect during use, not afterwards.
- Check duration. A few weeks of data cannot show where weight settles.
- Notice the comparator. A placebo arm that is followed after stopping gives the cleanest answer.
- Beware survivorship. People who drop out are often missing from the final numbers.
Limitations
These were large trials in selected populations with lifestyle support, so they may not apply to everyone. Averages hide wide individual variation. And as with all of the trial literature, generalizing across compounds needs direct evidence (see the evidence ladder).
The bottom line
The most important data point in weight research may be the one gathered after the treatment ends. It tells you whether an effect is a change in the underlying biology or a response during exposure.
Related reading
- Why Weight Loss Plateaus: Adaptive Thermogenesis, Leptin and Hunger Hormones in the Research
- The Appetite Hormone Map: Ghrelin, Leptin, PYY, GLP-1, CCK, Amylin and the Brain
- The Evidence Ladder: How to Read Peptide Research Without Being Fooled
- Browse the full Research Library
Explore Lucid Aminos
- Shop all research compounds
- Read the lab reports (COA)
- Monthly Research Panel
- Frequently asked questions
- Partner program
- About Lucid Aminos
- Contact us
For laboratory research use only. Not for human or veterinary use, and not intended to diagnose, treat, cure or prevent any condition. This article is educational and is not medical advice.